The present and future of tuberculosis vaccinations

Area of Science:

• Immunology
• Infectious Diseases
• Vaccinology

Background:

• Tuberculosis (TB) poses a significant global health burden, necessitating effective prevention strategies.
• The current Bacillus Calmette-Guérin (BCG) vaccine offers limited protection in adults, who are primary TB transmitters.
• Drug-resistant Mycobacterium tuberculosis (Mtb) strains and HIV co-infection complicate TB management.

Purpose of the Study:

• To highlight the urgent need for novel and improved tuberculosis vaccines.
• To discuss the potential of multi-antigen vaccines, including those targeting dormant Mtb strains.
• To emphasize the continued importance of BCG vaccination in specific populations.

Main Methods:

• Review of current literature on TB burden and prevention strategies.
• Analysis of the efficacy and limitations of the existing BCG vaccine.
• Evaluation of emerging multi-antigen vaccine candidates for Mtb.

Main Results:

• Existing TB vaccines show variable efficacy, particularly in adults.
• Newer vaccines incorporating multiple antigens, including those for dormant Mtb, are under development.
• BCG remains a foundational prophylactic measure for neonates and at-risk children.

Conclusions:

• Development of advanced TB vaccines is critical to address the ongoing global health challenge.
• Multi-antigen vaccines represent a promising avenue for enhanced TB prevention.
• BCG vaccination should be maintained in immunization schedules until superior alternatives are established.